Future Treatment Options for Patients With RCC

March 23, 2018
Hans Hammers, MD, PhD

Hans Hammers, MD, PhD, associate professor at the University of Texas Southwestern Medical Center, discusses what he believes is most important in future investigation for the treatment of patients with renal cell carcinoma. With combination therapies on the rise in the field of kidney cancers, new pivotal and early clinical trials are constantly arising looking at new combination regimens.

Hans Hammers, MD, PhD, associate professor at the University of Texas Southwestern Medical Center, discusses what he believes is most important in future investigation for the treatment of patients with renal cell carcinoma (RCC). With combination therapies on the rise in the field of kidney cancers, new pivotal and early clinical trials are constantly arising looking at new combination regimens.

A number of agents are heading toward clinical development that are also being tested in clinical trials as a part of potential combinations, especially with various immune checkpoint inhibitors. For example, Hammers pointed to an ongoing phase III trial of an IDO inhibitor, epacadostat, in combination with pembrolizumab (Keytruda), a PD-1 inhibitor, as a frontline treatment in comparison with sunitinib (Sutent), a current first-line standard-of-care targeted therapy in RCC. Hammers also suggested exploring the potential of vaccination with combinations of checkpoint inhibitors.